InSphero Named #1 Swiss Startup for 2014
News Oct 04, 2014
InSphero AG was recognized as the #1 company in the Top 100 Swiss Startups Rankings for 2014, per results published in Switzerland on September 18th. The honor marks the fourth consecutive year that InSphero has made the Top 10 in the rankings, but is the first time the company has been awarded the #1 overall startup designation across all industries.
Founded in 2009 in Zurich, Switzerland, InSphero now has commercial offices in Germany and the United States, and counts the world’s top 15 pharmaceutical and cosmetics companies amongst its customers. Already in 2014 the company has added novel 3D pancreatic microislets to its 3D InSight™ microtissue line, along with a spheroid imager, and 3D-optimized cytotoxicity assay kit that incorporates technology from Promega, the industry's leading provider of cell-based assays.
Dr. Jan Lichtenberg, Chief Executive Officer and co-founder of InSphero says the award is affirmation that the company’s effort to expand the reach of their customer base along with the breadth of their product portfolio are paying off. “We started with the mission to make 3D cell culture a robust and easy to use tool for more predictive drug testing. Today, all major pharma companies have InSphero products in-house. We are proud that the panel has recognized this success.”
InSphero, a spin-off of the ETH Zurich and the University of Zurich, placed fifth overall in the competition in 2013. The Swiss Startups Rankings are determined by a panel of 100 Swiss startup experts, each of whom individually names and ranks ten promising startup companies. Ten points are awarded to the top nominee on each list, down to one point for the tenth, and the startups with the highest combined points enter the Top 100 rankings.
New Class of Decoy Molecules that Prevent the Onset of PainNews
Researcher report a new method of reducing pain-associated behaviors with RNA-based medicine, creating a new class of decoy molecules that prevent the onset of pain.READ MORE
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
New Class of Drugs for the Treatment of Advanced Lung DiseaseNews
Researchers have demonstrated the potential of a new class of drugs for the treatment of refractory chronic obstructive pulmonary disease, i.e. COPD.READ MORE